Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose

Executive Summary

Roche and GlaxoSmithKline will support the launch of the osteoporosis therapy Boniva (ibandronate) with a program intended to help patients comply with the once-monthly oral dosing regimen

You may also be interested in...



The Year Ahead: Bisphosphonate Class Faces Generic Competition – Fosamax Goes Off Patent

Merck's Fosamax (alendronate) will be one of the key branded drugs facing generic competition in 2008, and the availability of a low-cost version of the market-leading osteoporosis drug could have a wide-reaching impact on the bisphosphonate class and beyond

The Year Ahead: Bisphosphonate Class Faces Generic Competition – Fosamax Goes Off Patent

Merck's Fosamax (alendronate) will be one of the key branded drugs facing generic competition in 2008, and the availability of a low-cost version of the market-leading osteoporosis drug could have a wide-reaching impact on the bisphosphonate class and beyond

Boniva I.V. Once-Quarterly Safety Concerns Few, But Renal Tests Advised

Roche/GlaxoSmithKline's once-quarterly osteoporosis therapy Boniva injection does not present serious safety concerns compared with oral bisphosphonates, labeling for the I.V. formulation of the drug suggests

Related Content

Topics

UsernamePublicRestriction

Register

PS045617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel